Mirum Pharmaceuticals Inc... Show more
a biopharmaceutical company. which focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| ENS.X | 5.754608 | 0.233243 | +4.22% |
| Ethereum Name Service cryptocurrency | |||
| AGLD.X | 0.164044 | 0.002364 | +1.46% |
| Adventure Gold cryptocurrency | |||
| ID.X | 0.031605 | 0.000120 | +0.38% |
| SPACE ID cryptocurrency | |||
| JANH | 25.06 | N/A | N/A |
| Innovator Premium Income 20 Bar ETF -Jan | |||
| HIGH.X | 0.029003 | -0.001000 | -3.33% |
| Highstreet cryptocurrency | |||
A.I.dvisor indicates that over the last year, MIRM has been loosely correlated with PCVX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MIRM jumps, then PCVX could also see price increases.
| Ticker / NAME | Correlation To MIRM | 1D Price Change % | ||
|---|---|---|---|---|
| MIRM | 100% | -2.38% | ||
| PCVX - MIRM | 45% Loosely correlated | +0.97% | ||
| XERS - MIRM | 45% Loosely correlated | -2.87% | ||
| EXEL - MIRM | 41% Loosely correlated | -2.28% | ||
| KURA - MIRM | 41% Loosely correlated | -1.56% | ||
| LKFT - MIRM | 40% Loosely correlated | N/A | ||
More | ||||
The RSI Oscillator for MIRM moved out of oversold territory on August 07, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 13 similar instances when the indicator left oversold territory. In 12 of the 13 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Moving Average Convergence Divergence (MACD) for MIRM just turned positive on August 26, 2026. Looking at past instances where MIRM's MACD turned positive, the stock continued to rise in 39 of 46 cases over the following month. The odds of a continued upward trend are 85%.
Following a +1.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where MIRM advanced for three days, in 235 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
MIRM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 59 cases where MIRM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 73%.
The Momentum Indicator moved below the 0 level on September 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MIRM as a result. In 69 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MIRM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.
The Aroon Indicator for MIRM entered a downward trend on August 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Profit vs. Risk Rating rating for this company is 15 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. MIRM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (26.596) is normal, around the industry mean (19.994). P/E Ratio (0.000) is within average values for comparable stocks, (27.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.527). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (8.913) is also within normal values, averaging (427.627).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.